These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 15370132

  • 1. Experiences in providing a screening service for colorectal cancer from a pathology laboratory.
    Edwards JE, Williams JA, Thomas DW.
    Pathology; 2004 Aug; 36(4):330-4. PubMed ID: 15370132
    [Abstract] [Full Text] [Related]

  • 2. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.
    Hoepffner N, Shastri YM, Hanisch E, Rösch W, Mössner J, Caspary WF, Stein J.
    Aliment Pharmacol Ther; 2006 Jan 01; 23(1):145-54. PubMed ID: 16393292
    [Abstract] [Full Text] [Related]

  • 3. Colorectal cancer mass screening event utilising quantitative faecal occult blood test.
    Chew MH, Suzanah N, Ho KS, Lim JF, Ooi BS, Tang CL, Eu KW.
    Singapore Med J; 2009 Apr 01; 50(4):348-53. PubMed ID: 19421676
    [Abstract] [Full Text] [Related]

  • 4. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F, Marino B, DeVecchi N, Moretti R, Lecco Colorectal Cancer Screening Group, Ucci G, Tricomi P, Armellino A, Redaelli L, Bargiggia S, Cristofori E, Masala E, Tortorella F, Gattinoni A, Odinolfi F, Pirola ME.
    Br J Surg; 2009 May 01; 96(5):533-40. PubMed ID: 19358181
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A 25-year follow-up of a population screened with faecal occult blood test in Finland.
    Malila N, Hakama M, Pukkala E.
    Acta Oncol; 2007 May 01; 46(8):1103-6. PubMed ID: 17851857
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.
    Malila N, Oivanen T, Hakama M.
    Z Gastroenterol; 2008 Apr 01; 46 Suppl 1():S25-8. PubMed ID: 18368636
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Niv Y.
    Aliment Pharmacol Ther; 2006 Nov 15; 24(10):1475-81. PubMed ID: 17032281
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS, Liao CS, Chang SH, Lai HC, Chen TH.
    J Med Screen; 2007 Nov 15; 14(4):191-9. PubMed ID: 18078564
    [Abstract] [Full Text] [Related]

  • 14. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population.
    Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y.
    Gastroenterology; 2005 Aug 15; 129(2):422-8. PubMed ID: 16083699
    [Abstract] [Full Text] [Related]

  • 15. Lower gastrointestinal symptoms are not predictive of colorectal neoplasia in a faecal occult blood screen-positive population.
    Ahmed S, Leslie A, Thaha MA, Carey FA, Steele RJ.
    Br J Surg; 2005 Apr 15; 92(4):478-81. PubMed ID: 15609377
    [Abstract] [Full Text] [Related]

  • 16. High yield of colorectal neoplasia detected by colonoscopy following a positive faecal occult blood test in the NHS Bowel Cancer Screening Programme.
    Lee TJ, Clifford GM, Rajasekhar P, Rutter MD, Kometa S, Ritchie MC, Waddup G, Nylander D, McNally RJ, Rees CJ.
    J Med Screen; 2011 Apr 15; 18(2):82-6. PubMed ID: 21852700
    [Abstract] [Full Text] [Related]

  • 17. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test.
    Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y.
    Aliment Pharmacol Ther; 2006 May 01; 23(9):1359-64. PubMed ID: 16629942
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fecal occult blood testing for colorectal cancer in an ethnically diverse population.
    Glober GA, Hundahl S, Stucke J, Choy M.
    West J Med; 1994 Oct 01; 161(4):377-82. PubMed ID: 7817548
    [Abstract] [Full Text] [Related]

  • 20. Green-coloured results on guaiac-based faecal occult blood testing should be considered positive.
    Skitek M.
    Ann Clin Biochem; 2005 May 01; 42(Pt 3):234-5; author reply 235. PubMed ID: 15949162
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.